Frontiers in Pharmacology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2160142, encodeId=9cd721601429f, content=自引率6.3，国人占比100%，会踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Thu Sep 28 08:20:17 CST 2023, time=2023-09-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2162001, encodeId=d220216200127, content=请问大家review finalized以后几天？最后结果如何，谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3618230763, createdName=桑葚大友, createdTime=Tue Oct 10 17:13:05 CST 2023, time=2023-10-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2154508, encodeId=cb0c215450890, content=请问有要求提供组学分析代码的吗？相关图片生成是组学相关生物公司提供的，人家也不给代码啊，我这是不是得撤稿了，没希望了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Aug 25 10:39:50 CST 2023, time=2023-08-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2104998, encodeId=98d12104998f3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：Meta分析 经验分享：请问发表后pubmed上能检索到需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep1HeUOlIoagypwfVbQuVCiaGM87PvQBWTmHPYNkic30KtOA1YZZyxrQUobKbQ545FAicyXQ6khht0vQ/132, createdBy=37681676512, createdName=南山晓月ZARD, createdTime=Thu Dec 08 22:30:08 CST 2022, time=2022-12-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2158271, encodeId=dc8121582e17c, content=补充材料有表格和图片。请问，图片是单独上传，还是放在WORD里和表格一起上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Mon Sep 18 12:21:29 CST 2023, time=2023-09-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省)]

2023-12-04 ms5000001006994240 来自山东省

各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？

44 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2160142, encodeId=9cd721601429f, content=自引率6.3，国人占比100%，会踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Thu Sep 28 08:20:17 CST 2023, time=2023-09-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2162001, encodeId=d220216200127, content=请问大家review finalized以后几天？最后结果如何，谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3618230763, createdName=桑葚大友, createdTime=Tue Oct 10 17:13:05 CST 2023, time=2023-10-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2154508, encodeId=cb0c215450890, content=请问有要求提供组学分析代码的吗？相关图片生成是组学相关生物公司提供的，人家也不给代码啊，我这是不是得撤稿了，没希望了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Aug 25 10:39:50 CST 2023, time=2023-08-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2104998, encodeId=98d12104998f3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：Meta分析 经验分享：请问发表后pubmed上能检索到需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep1HeUOlIoagypwfVbQuVCiaGM87PvQBWTmHPYNkic30KtOA1YZZyxrQUobKbQ545FAicyXQ6khht0vQ/132, createdBy=37681676512, createdName=南山晓月ZARD, createdTime=Thu Dec 08 22:30:08 CST 2022, time=2022-12-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2158271, encodeId=dc8121582e17c, content=补充材料有表格和图片。请问，图片是单独上传，还是放在WORD里和表格一起上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Mon Sep 18 12:21:29 CST 2023, time=2023-09-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省)]

2023-10-11 科研-小白来自山西省

Initial Validation大家用了多久，我提交原始数据第5天没动静

158 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2160142, encodeId=9cd721601429f, content=自引率6.3，国人占比100%，会踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Thu Sep 28 08:20:17 CST 2023, time=2023-09-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2162001, encodeId=d220216200127, content=请问大家review finalized以后几天？最后结果如何，谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3618230763, createdName=桑葚大友, createdTime=Tue Oct 10 17:13:05 CST 2023, time=2023-10-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2154508, encodeId=cb0c215450890, content=请问有要求提供组学分析代码的吗？相关图片生成是组学相关生物公司提供的，人家也不给代码啊，我这是不是得撤稿了，没希望了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Aug 25 10:39:50 CST 2023, time=2023-08-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2104998, encodeId=98d12104998f3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：Meta分析 经验分享：请问发表后pubmed上能检索到需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep1HeUOlIoagypwfVbQuVCiaGM87PvQBWTmHPYNkic30KtOA1YZZyxrQUobKbQ545FAicyXQ6khht0vQ/132, createdBy=37681676512, createdName=南山晓月ZARD, createdTime=Thu Dec 08 22:30:08 CST 2022, time=2022-12-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2158271, encodeId=dc8121582e17c, content=补充材料有表格和图片。请问，图片是单独上传，还是放在WORD里和表格一起上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Mon Sep 18 12:21:29 CST 2023, time=2023-09-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省)]

2023-09-28 jobhnw 来自安徽省

自引率6.3，国人占比100%，会踢么

45 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2160142, encodeId=9cd721601429f, content=自引率6.3，国人占比100%，会踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Thu Sep 28 08:20:17 CST 2023, time=2023-09-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2162001, encodeId=d220216200127, content=请问大家review finalized以后几天？最后结果如何，谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3618230763, createdName=桑葚大友, createdTime=Tue Oct 10 17:13:05 CST 2023, time=2023-10-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2154508, encodeId=cb0c215450890, content=请问有要求提供组学分析代码的吗？相关图片生成是组学相关生物公司提供的，人家也不给代码啊，我这是不是得撤稿了，没希望了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Aug 25 10:39:50 CST 2023, time=2023-08-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2104998, encodeId=98d12104998f3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：Meta分析 经验分享：请问发表后pubmed上能检索到需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep1HeUOlIoagypwfVbQuVCiaGM87PvQBWTmHPYNkic30KtOA1YZZyxrQUobKbQ545FAicyXQ6khht0vQ/132, createdBy=37681676512, createdName=南山晓月ZARD, createdTime=Thu Dec 08 22:30:08 CST 2022, time=2022-12-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2158271, encodeId=dc8121582e17c, content=补充材料有表格和图片。请问，图片是单独上传，还是放在WORD里和表格一起上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Mon Sep 18 12:21:29 CST 2023, time=2023-09-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省)]

2023-10-10 桑葚大友来自山东省

请问大家review finalized以后几天？最后结果如何，谢谢大家。

38 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2160142, encodeId=9cd721601429f, content=自引率6.3，国人占比100%，会踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Thu Sep 28 08:20:17 CST 2023, time=2023-09-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2162001, encodeId=d220216200127, content=请问大家review finalized以后几天？最后结果如何，谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3618230763, createdName=桑葚大友, createdTime=Tue Oct 10 17:13:05 CST 2023, time=2023-10-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2154508, encodeId=cb0c215450890, content=请问有要求提供组学分析代码的吗？相关图片生成是组学相关生物公司提供的，人家也不给代码啊，我这是不是得撤稿了，没希望了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Aug 25 10:39:50 CST 2023, time=2023-08-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2104998, encodeId=98d12104998f3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：Meta分析 经验分享：请问发表后pubmed上能检索到需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep1HeUOlIoagypwfVbQuVCiaGM87PvQBWTmHPYNkic30KtOA1YZZyxrQUobKbQ545FAicyXQ6khht0vQ/132, createdBy=37681676512, createdName=南山晓月ZARD, createdTime=Thu Dec 08 22:30:08 CST 2022, time=2022-12-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2158271, encodeId=dc8121582e17c, content=补充材料有表格和图片。请问，图片是单独上传，还是放在WORD里和表格一起上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Mon Sep 18 12:21:29 CST 2023, time=2023-09-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省)]

2023-08-25 1378327198@qq.com 来自湖南省

请问有要求提供组学分析代码的吗？相关图片生成是组学相关生物公司提供的，人家也不给代码啊，我这是不是得撤稿了，没希望了？

65 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2160142, encodeId=9cd721601429f, content=自引率6.3，国人占比100%，会踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Thu Sep 28 08:20:17 CST 2023, time=2023-09-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2162001, encodeId=d220216200127, content=请问大家review finalized以后几天？最后结果如何，谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3618230763, createdName=桑葚大友, createdTime=Tue Oct 10 17:13:05 CST 2023, time=2023-10-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2154508, encodeId=cb0c215450890, content=请问有要求提供组学分析代码的吗？相关图片生成是组学相关生物公司提供的，人家也不给代码啊，我这是不是得撤稿了，没希望了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Aug 25 10:39:50 CST 2023, time=2023-08-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2104998, encodeId=98d12104998f3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：Meta分析 经验分享：请问发表后pubmed上能检索到需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep1HeUOlIoagypwfVbQuVCiaGM87PvQBWTmHPYNkic30KtOA1YZZyxrQUobKbQ545FAicyXQ6khht0vQ/132, createdBy=37681676512, createdName=南山晓月ZARD, createdTime=Thu Dec 08 22:30:08 CST 2022, time=2022-12-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2158271, encodeId=dc8121582e17c, content=补充材料有表格和图片。请问，图片是单独上传，还是放在WORD里和表格一起上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Mon Sep 18 12:21:29 CST 2023, time=2023-09-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省)]

2022-12-08 南山晓月ZARD 来自辽宁省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：Meta分析
经验分享：请问发表后pubmed上能检索到需要多长时间？

143 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2160142, encodeId=9cd721601429f, content=自引率6.3，国人占比100%，会踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Thu Sep 28 08:20:17 CST 2023, time=2023-09-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2162001, encodeId=d220216200127, content=请问大家review finalized以后几天？最后结果如何，谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3618230763, createdName=桑葚大友, createdTime=Tue Oct 10 17:13:05 CST 2023, time=2023-10-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2154508, encodeId=cb0c215450890, content=请问有要求提供组学分析代码的吗？相关图片生成是组学相关生物公司提供的，人家也不给代码啊，我这是不是得撤稿了，没希望了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Aug 25 10:39:50 CST 2023, time=2023-08-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2104998, encodeId=98d12104998f3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：Meta分析 经验分享：请问发表后pubmed上能检索到需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep1HeUOlIoagypwfVbQuVCiaGM87PvQBWTmHPYNkic30KtOA1YZZyxrQUobKbQ545FAicyXQ6khht0vQ/132, createdBy=37681676512, createdName=南山晓月ZARD, createdTime=Thu Dec 08 22:30:08 CST 2022, time=2022-12-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2158271, encodeId=dc8121582e17c, content=补充材料有表格和图片。请问，图片是单独上传，还是放在WORD里和表格一起上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Mon Sep 18 12:21:29 CST 2023, time=2023-09-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省)]

2023-09-18 重复的用户名来自浙江省

补充材料有表格和图片。请问，图片是单独上传，还是放在WORD里和表格一起上传？

50 0

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2160142, encodeId=9cd721601429f, content=自引率6.3，国人占比100%，会踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Thu Sep 28 08:20:17 CST 2023, time=2023-09-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2162001, encodeId=d220216200127, content=请问大家review finalized以后几天？最后结果如何，谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3618230763, createdName=桑葚大友, createdTime=Tue Oct 10 17:13:05 CST 2023, time=2023-10-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2154508, encodeId=cb0c215450890, content=请问有要求提供组学分析代码的吗？相关图片生成是组学相关生物公司提供的，人家也不给代码啊，我这是不是得撤稿了，没希望了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Aug 25 10:39:50 CST 2023, time=2023-08-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2104998, encodeId=98d12104998f3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：Meta分析 经验分享：请问发表后pubmed上能检索到需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep1HeUOlIoagypwfVbQuVCiaGM87PvQBWTmHPYNkic30KtOA1YZZyxrQUobKbQ545FAicyXQ6khht0vQ/132, createdBy=37681676512, createdName=南山晓月ZARD, createdTime=Thu Dec 08 22:30:08 CST 2022, time=2022-12-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2158271, encodeId=dc8121582e17c, content=补充材料有表格和图片。请问，图片是单独上传，还是放在WORD里和表格一起上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Mon Sep 18 12:21:29 CST 2023, time=2023-09-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省)]

2021-07-29 若氵离

偏重的研究方向：心血管药理学
经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？

76 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2160142, encodeId=9cd721601429f, content=自引率6.3，国人占比100%，会踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Thu Sep 28 08:20:17 CST 2023, time=2023-09-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2162001, encodeId=d220216200127, content=请问大家review finalized以后几天？最后结果如何，谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3618230763, createdName=桑葚大友, createdTime=Tue Oct 10 17:13:05 CST 2023, time=2023-10-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2154508, encodeId=cb0c215450890, content=请问有要求提供组学分析代码的吗？相关图片生成是组学相关生物公司提供的，人家也不给代码啊，我这是不是得撤稿了，没希望了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Aug 25 10:39:50 CST 2023, time=2023-08-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2104998, encodeId=98d12104998f3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：Meta分析 经验分享：请问发表后pubmed上能检索到需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep1HeUOlIoagypwfVbQuVCiaGM87PvQBWTmHPYNkic30KtOA1YZZyxrQUobKbQ545FAicyXQ6khht0vQ/132, createdBy=37681676512, createdName=南山晓月ZARD, createdTime=Thu Dec 08 22:30:08 CST 2022, time=2022-12-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2158271, encodeId=dc8121582e17c, content=补充材料有表格和图片。请问，图片是单独上传，还是放在WORD里和表格一起上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Mon Sep 18 12:21:29 CST 2023, time=2023-09-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省)]

2022-09-06 ms4000001680289394

偏重的研究方向：民族药理学;中药复方
经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄

222 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172843, encodeId=b0c721e284362, content=各位大神们，请问提交WB原始数据是文章中出现的就行还是要提交三次重复的WB原始数据啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4f8508995, createdName=ms5000001006994240, createdTime=Mon Dec 04 12:19:29 CST 2023, time=2023-12-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2162179, encodeId=7a9d21621e99f, content=Initial Validation大家用了多久，我提交原始数据第5天没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=726d8808692, createdName=科研-小白, createdTime=Wed Oct 11 14:04:09 CST 2023, time=2023-10-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2160142, encodeId=9cd721601429f, content=自引率6.3，国人占比100%，会踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9be1604114, createdName=jobhnw, createdTime=Thu Sep 28 08:20:17 CST 2023, time=2023-09-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2162001, encodeId=d220216200127, content=请问大家review finalized以后几天？最后结果如何，谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3618230763, createdName=桑葚大友, createdTime=Tue Oct 10 17:13:05 CST 2023, time=2023-10-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2154508, encodeId=cb0c215450890, content=请问有要求提供组学分析代码的吗？相关图片生成是组学相关生物公司提供的，人家也不给代码啊，我这是不是得撤稿了，没希望了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3305447324, createdName=1378327198@qq.com, createdTime=Fri Aug 25 10:39:50 CST 2023, time=2023-08-25, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2104998, encodeId=98d12104998f3, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：Meta分析 经验分享：请问发表后pubmed上能检索到需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep1HeUOlIoagypwfVbQuVCiaGM87PvQBWTmHPYNkic30KtOA1YZZyxrQUobKbQ545FAicyXQ6khht0vQ/132, createdBy=37681676512, createdName=南山晓月ZARD, createdTime=Thu Dec 08 22:30:08 CST 2022, time=2022-12-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2158271, encodeId=dc8121582e17c, content=补充材料有表格和图片。请问，图片是单独上传，还是放在WORD里和表格一起上传？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35ef5508120, createdName=重复的用户名, createdTime=Mon Sep 18 12:21:29 CST 2023, time=2023-09-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1003537, encodeId=7ed3100353e7d, content=偏重的研究方向：心血管药理学 经验分享：请问朋友们，frontiers in pharmacology这个杂志社需不需要原始数据啊，我的文章现在处于Review Finalized，两个审稿人均已同意收稿，但是编辑提了不少问题。目前为止还未通知我上传原始记录，我想问下会要吗？大概什么时候要？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=38205516444, createdName=若氵离, createdTime=Thu Jul 29 10:20:59 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133754, encodeId=26252133e54f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：综述 经验分享：09 May 2023 Article accepted for publication. 02 May 2023 Review of Review Editor 3 finalized. 28 Apr 2023 Submitting Author posted new comments in the Editor tab. Submitting Author re-submitted manuscript. You posted new comments. 16 Apr 2023 Reviewer 3 posted new comments. 15 Apr 2023 Submitting Author re-submitted manuscript. You posted new comments. Submitting Author posted new comments in the Editor tab. 06 Apr 2023 Interactive review forum activated. 05 Apr 2023 Review of Reviewer 1 is finalized. 04 Apr 2023 Review of Reviewer 2 is finalized. 23 Mar 2023 Submitting Author submitted manuscrip, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64f46563607, createdName=ms1000000861767492, createdTime=Sun May 14 16:38:06 CST 2023, time=2023-05-14, status=1, ipAttribution=吉林省)]

2023-05-14 ms1000000861767492 来自吉林省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：综述
经验分享：09 May 2023
Article accepted for publication.
02 May 2023
Review of Review Editor 3 finalized.
28 Apr 2023
Submitting Author posted new comments in the Editor tab.
Submitting Author re-submitted manuscript.
You posted new comments.
16 Apr 2023
Reviewer 3 posted new comments.
15 Apr 2023
Submitting Author re-submitted manuscript.
You posted new comments.
Submitting Author posted new comments in the Editor tab.
06 Apr 2023
Interactive review forum activated.
05 Apr 2023
Review of Reviewer 1 is finalized.
04 Apr 2023
Review of Reviewer 2 is finalized.
23 Mar 2023
Submitting Author submitted manuscrip

92 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务